June 15, Proprietary blending concept for Natural Bladder Support for Women & Men

Similar documents
A review of the clinical and safety data on DROPSORDRY TM

A Breakthrough in the Relief of Overactive Bladder and Urinary Incontinence

Diane K. Newman DNP, ANP-BC, PCB-PMD, FAAN

Study No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July-August

URINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara

Dr. Aso Urinary Symptoms

Appendix F: Continence Care and Bowel Management Program Training Presentation. Audience: For Front-line Staff Release Date: December 22, 2010

Coping with urges and leaks?

Please complete this voiding diary and questionnaire. Bring both of them with you to your next appointment with your provider.

Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2

Management of Urinary Incontinence in Older Women. Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital

Module 3 Causes Of Urinary Incontinence

Urinary Incontinence. Lora Keeling and Byron Neale

Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based

Overview of comments received on Community herbal monograph on Cucurbita pepo L, semen (EMA/HMPC/136024/2010)

Paediatric Urotherapy Training

Posterior Tibial Nerve Stimulation

Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC

Overactive bladder can result from one or more of the following causes:

David Henry Jablonski, M.D North Mills Avenue Orlando, FL 32803

Jeffrey Richard Thill, M.D North Mills Avenue Orlando, FL 32803

Overactive Bladder Syndrome

Updates in the nonpharmacological. treatment on overactive bladder

A BREAKTHROUGH IN THE RELIEF OF OVERACTIVE BLADDER AND URINARY INCONTINENCE

Fang-Chi Chang (M.D.,Ph.D.) Center for Drug Evaluation, Taiwan

CDEC FINAL RECOMMENDATION

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Latest Press Release. sbn network jimmy swaggart comcast

Urinary Incontinence in Women: Never an Acceptable Consequence of Aging

Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist

Table 1. International Consultation on Incontinence recommendations for frail older adults

Bladder dysfunction in ALD and AMN

Diagnosis and Mangement of Nocturia in Adults

Patient Information. Basic Information on Overactive Bladder Symptoms. pubic bone. urethra. scrotum. bladder. vaginal canal

IMPROVING URINARY INCONTINENCE

Prostate Enlargement Reduction

MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH

Presented by Grace Smith CNC Latrobe Regional Hospital Continence Clinic

Neurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.

The patient, your co-pilot in assessing LUTS

Using Physiotherapy to Manage Urinary Incontinence in Women

CLINICIAN INTERVIEW SPECIFIC FACTORS OF NOCTURIA: A SPECIALIST PERSPECTIVE. An interview with Eric S. Rovner, MD

Nocdurna (desmopressin acetate) NEW PRODUCT SLIDESHOW

THE OVER-ACTIVE BLADDER (OAB)

Overview. Methods of assessment. Assessment of LUTS. Patient Assessment and Bladder Diary 15/05/2017. How are LUTS and quality of life (QoL) assessed?

Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital

Glossary of terms Urinary Incontinence

Pelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS

Cucurbita pepo semen. Kürbissamen Pumpkin seeds

When Laughing is No Longer Funny Managing Transient Urinary Incontinence in Hospitalized Elderly Women

SELECTED POSTER PRESENTATIONS

Urinary Incontinence? - gør dig ikke skakmat...

Management of Incontinence and Pelvic Floor Disorders

Continence Worksheet Name: Date: Name of Trainer: Name of Company: Clinical Update (NZ) Ltd

Urinary Incontinence. a problem for many

Diagnosis and Treatment of Urinary Incontinence. Urinary Incontinence

Urinary Incontinence for the Primary Care Provider

Urogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018

Urodynamics in women. Aims of Urodynamics in women. Why do Urodynamics?

Various Types. Ralph Boling, DO, FACOG

Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.

H6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)

Advanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa

Appendix E: Continence Care and Bowel Management Program Training Presentation. Audience: For Registered Staff Release Date: December 22, 2010

Overactive Bladder: Diagnosis and Approaches to Treatment

Management of Female Stress Incontinence

Overview. Methods of assessment. Assessment of LUTS. Methods of self-report assessment. Why use self-report instruments 11/12/2015

Overactive bladder syndrome (OAB)

Open Clinical Study of Effects of Pumpkin Seed Extract/ Soybean Germ Extract Mixture-containing Processed Food on Nocturia

Retrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder

Objectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS

Y0028_2726_0 File&Use Bladder Control Does Matter

Hydrating, effervescent, tasty. Offsets any calcium and vitamin C deficiencies INDICATIONS DESCRIPTION CHARACTERISTICS COMMERCIAL OFFER DESCRIPTION

Diagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center

5 Reasons Why It s the #1 Ingredient Opportunity. EFSA Claims Approved

PREVENTING URINARY INCONTINENCE through PELVIC FLOOR REHABILITATION in DISABLED ELDERLY

Survey on micturition disorders, surgical procedures and therapeutic approaches in patients treated for gynecologic cancers in clinical settings

New Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital

The Management of Female Urinary Incontinence. Part 1: Aetiology and Investigations

A SURVEY ON LOWER URINARY TRACT SYMPTOMS (LUTS) AMONG PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) IN HOSPITAL UNIVERSITI SAINS MALAYSIA (HUSM)

URINARY INCONTINENCE FOR FALLS PREVENTION. by Susan Elms P.T. Elms Physiotherapy

Information for Patients. Overactive bladder syndrome (OAB) English

D-MANNOSE, CRANBERRY AND VITAMIN C (CYSTOMAN 100MG) ARE EFFECTIVE IN PREVENTING URINARY TRACT INFECTIONS IN MULTIPLE SCLEROSIS SUBJECTS.

Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders

Dr. Melissa Kagarise, PA C

Outpatient Rehabilitation Services

Incontinence: Risks, Causes and Care

Most Men May Experience BPH

Overactive Bladder in Clinical Practice

Urogynecology Associates of Philadelphia URODYNAMIC TESTING

TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH

INCONTINENCE. Continence and Pelvic Floor Rehabilitation TYPES OF INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE 11/08/2015

Patient Information. Lower Urinary Tract Symptoms (LUTS) and Diagnosis of BPE

Clinical guidelines for overactive bladder

Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia

Disease Management. Incontinence Care. Chan Sau Kuen Continence Nurse Consultant United Christian Hospital 14/11/09

Effectiveness of Non Steroidal Anti Inflamatery Drug "Diclofenac Sodium" in Treatment of Nocturia in Benign Prostatic Hyperplasia Patien

Night-time visits to the toilet?

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Urinary incontinence: the management of urinary incontinence in women

Transcription:

June 15, 2011 Proprietary blending concept for Natural Bladder Support for Women & Men

Go Less to the Toilet

For what stands? GoLess is a registered concept for urinary health which stands for 3 different options: 1. 1+1 = Single ingredients: EFLA 940 & Soylife 40 2. GMP Blend FRCH: 3. Non GMP Blend FRUS: EFLA 940 SoyLife 40

Is a pure naturalsolution: Proprietaryblending conceptof PumpkinseedextractEFLA 940and SoyLife 40% Patented: EFLA HyperPure process SoyLife soy germ patents (PMS and Menopause) General Efficacy and safety supported by proprietary studies Drug Master Files available for EFLA 940 and SoyLife 40% Co-branding opportunities New logo available since 2011 Frutarom own products and fully supported globally Informative website available www.go-less.com

Positioning GoLess is a registered concept for the combination of Pumpkin Seed Extract (EFLA 940) and SoyLife 40% which allows us to offer tailor made solutions GoLess is a registered concept for urinary health which is backed up with proprietary studies This concept offers you different puchasing options: 1. Obtain seperate ingredients (EFLA 940 & SoyLife 40%) 2. Obtain the GMP blend from Frutarom Switzerland 3. Obtain non GMP blend from Frutarom US

for Urinary Health Overactive bladder( & ) Stress incontinence ( ) Indication X X

Stress incontinence:

Adresses the cause of overactive bladder (in women and men): Relaxation of bladder wall ACTIVITY Addresses the cause of stress incontinence in (postmenopausal) women: Strengthening of pelvic floor & spincter muscles Supports elasticity of urethral wall

Pumpkin Seed (EFLA 940) & Ingredient EFLA 940 Pumpkin Seed SoyLife 40 % Activity profile Strengtheningof pelvicfloor& sphincter muscles Relaxation of bladder wall Slowed down growth of prostate tissue Supports elasticity of urethral wall Health condition Overactivebladderand urinary incontinence Benign prostate hyperplasia Overactivebladderand urinary incontinence

Proprietary Studies overview Sogabe H. und Terado T. (2001), Open Clinical Study of Effects of Pumpkin Seed Extract/Soybean Germ Yanagisawa, Ei et al (2003), Study of Effectiveness of Mixed processed Fodd Containing Curcubita Pepo Seed Extract and Soybean Seed Extract on Stress Urinary Incontinence in Women Terado T et al. (2004), Clinical Study of mixed processed foods containing pumpkin seed extract and soybean germ extract on pollikiuria in night in elderly men BongseokShim et al. (2010, not published), Evaluation on the Functionality of Cucuflavonefor Improvement of Overactive Bladder-related Voiding Dysfunction and Quality of Life

Koreanclinicalstudy2010 Evaluation on the Functionality of Cucuflavonefor Improvement of Overactive Bladder-related Voiding Dysfunction and Quality of Life

STUDY Clinical (Bongseok Shim et al. 2010, Korea, not published) Decrease in urination frequency Decrease of frequency of urgency Decrease in nocturia frequency Dosage: 2 x 500 mg GoLess / day Purpose of this study was to approve the results of the previous studies done in Japan where another soy germ extract was used In this new Korean study both Frutarom extracts were used (EFLA 940 and SoyLife 40%) and the results of the previous studies were confirmed by using SoyLife 40%

Studydesign: 120 Koreanwomen, aged 35-70 years At least3 months symptoms of overactive bladder: > 8x / day > 2x duringnight. Urge incontinence 2x 500mg GoLess, during 12 weeks Parameters: Safety: Vitalsigns(BP, pulse); Bloodanalysis; Reported side effects Efficacy: Bladder diary Flow rate and remaining urine OAB-q V8 to evaluate overactive bladder syndrome and quality of life SQoL-F: sexual quality of life questionnaire female

Mainoutcomes:

Daily average frequency of urination (times) 11 GoLess Placebo 10 Frequency 9 8 P<0.0001 P<0.01 7 1 2 3 4 0 4 8 12 week Daily average frequency of urination: - 27%

Daily average frequency of urgency (times) Frequency 8 7 6 5 P<0.0001 NS GoLess Placebo 4 01 42 38 12 4 week Daily average frequency of urgency: - 31%

Average frequency of nocturia (times) 3 GoLess Placebo Frequency 2 P<0.0001 NS 1 01 42 83 12 4 week Average frequency of nocturia: - 31%

Subjective satisfaction level 100% 80% 60% 40% Not helpful Helpful Very helpful 20% 0% Placebo GoLess Subjective satisfaction level: > 90%

Summary : Statistically significant improvements were observed in the most important factors of overactive bladder syndrome : Urination frequency Nocturia frequency Frequency of urgency Safety was confirmed by absence of adverse effects reported, and parameters of blood analysis and vital signs were within normal range The subjective satisfaction level was over 90% with all the tested persons

Japanese clinical studies

STUDIES Clinical (SogabeH. et al. (2001) (YanagisawaEi et. Al., Japan (2003)) Decrease in urination frequency during the day Decrease in urination frequency during the night Reduction of incontinence episodes Improved sleep satisfaction High subjective improvement rate Dosage: 525 mg EFLA 940 + 30 mg soy germ isoflavones/ day

STUDIES Clinical (TeradoT. et al. (2004) Japan) Decrease in urination frequency during the night Improved sleep satisfaction High subjective improvement rate High compliance and safety Dosage: 525 mg EFLA 940 + 30 mg soy germ isoflavones/ day

Summary Brand new study results showed: Statistically significant improvements in the most important factors of overactive bladder syndrome in women : Urination frequency; Nocturnal frequency; Frequency of urgency Decreased of frequency of nocturnal and diurnal micturitions confirmed in human studies: both men and women GoLess significantly improved urinary incontinence in postmenopausal women and thereby significantly improve mobility and quality of life of affected individuals. GoLess is safe and effective for use in dietary supplements to support bladder health

Dosage recommendation DOSAGE 600 mg/day(525 mg EFLA 940& 75 mg SoyLife 40%)

Flexible Applications Capsules Tablets Powdered beverages Bladder Support formulations Women s specific formulations Prostate OTC formulations

Summary Quality Proprietary, patent protected blending concept of Frutarom ingredients EFLA 940is very stableand due to the patentedhyperpureprocess used it is absolutely free of oxidized lipidsunlike many other Pumpkin seed preparations. EFLA 940is produced with a validated and patented manufacturing process therefore reflecting a true multi-component system maintaining all active constituents SoyLife clinically studied for effectiveness and safety; patent protected ingredient (PMS and Menopause) Made from soy germ; standardized on isoflavones

Our Assurance Your Success Quality - Conformswith monographs (EFLA 940) - Validated procedures -EFLA Hyperpurepatent; Soy germ patents - SoyLife : Halal and Kosher certified Efficacy - Pharmacological studies in vitroand in vivo - Clinical studies on humans Significant effects Safety - Part of daily diet - Use over centuries - Toxicity studies

Uretin 45+ (Scandinavia) 525 mg EFLA 940 100 mg Soy germ extract Some current Products in the market Verikan (NL) Go-Less Maximum-Strength Bladder Control (USA) Bladder Control Formula (USA) 525 mg EFLA 940 75 mg SoyLife 40% 260 mg Magnesium

Thank you!